Repligen to Report Third Quarter 2019 Financial Results
October 23 2019 - 9:29AM
Repligen Corporation (NASDAQ:RGEN) today announced that the Company
will report its third quarter 2019 financial results on Thursday,
October 31, 2019. The Company will issue a press release before the
market opens and will host a conference call at 8:30 a.m. EDT to
discuss business updates and financial results for the three- and
nine-month reporting periods ended September 30, 2019.
The conference call will be accessible by dialing toll-free
(844) 701-1063 for domestic callers and (412) 317-5487 for
international callers. No passcode is required for the live call.
In addition, a webcast will be accessible via the Investor
Relations section of the Company’s website. Both the conference
call and webcast will be archived for a period of time following
the live event. The replay dial-in numbers are (877) 344-7529 for
callers in the U.S., (855) 669-9658 for callers in Canada and (412)
317-0088 for international callers. Replay listeners must provide
the passcode 10136347.
About Repligen CorporationRepligen Corporation
is a global life sciences company that develops and commercializes
highly innovative bioprocessing technologies and systems that
increase efficiencies in the process of manufacturing biological
drugs. We are inspiring advances in bioprocessing for the customers
we serve; primarily biopharmaceutical drug developers and contract
development and manufacturing organizations (CDMO’s) worldwide. Our
corporate headquarters are located in Waltham, MA (USA), and we
have additional administrative and manufacturing operations in
Marlborough, MA; Bridgewater, NJ; Rancho Dominguez, CA; Lund,
Sweden; Breda, The Netherlands and Ravensburg, Germany.
This press release may contain forward-looking
statements within the meaning of the federal securities laws.
Investors are cautioned that statements in this press release which
are not strictly historical statements including, without
limitation, statements identified by words like “believe,”
“expect,” “may,” “will,” “should,” “seek,” or “could” and similar
expressions, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated, including risks discussed from time to time
in our filings with the Securities and Exchange Commission. We
expressly disclaim any responsibility to update any forward-looking
statements, except as required by law.
Repligen Contact: Sondra
S. NewmanGlobal Head of Investor Relations(781)
419-1881investors@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From May 2023 to May 2024